Follow @TheHPRA
Contact us
As Gaeilge
My HPRA:
Login
Register
About Us
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Medicines
Safety Notices
My HPRA:
Login
Register
About Us
Medicines
COVID-19 vaccines and treatments
Our Role
Medicines Information
Safety Information
Safety Notices
Quality Information
Regulatory Information
News & Events
Special Topics
Emergency Medicines
Emergency Contact Details
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Nulojix (belatacept) Important Safety Information from Bristol-Myers Squibb Pharmaceuticals as approved by the Irish Medicines Board
Notice type:
3rd Party Publications
Date:
20/03/2013
Problem Or Issue:
Important Safety Information communication from Bristol-Myers Squibb Pharmaceuticals on increased rate of acute graft rejection with Nulojix (belatacept) associated with rapid corticosteroid taper in patients at high immunologic risk for acute rejection.
Important Safety Information - Nulojix (belatacept)
« Back
Date Printed: 28/04/2024